#principle
- 成功费触发条件必须同时约束结果变量与测量质量 20260425182313000
- 桥接 offer 的最小可验证结构 20260425182107000
- 结果导向/分成式报价的零EV门槛通常更苛刻 20260425181936000
- 顺序干预的洗脱间隔先用药代锚定保守下界 20260425181535000
- 来源归因误差预算 20260425181416000
- 固定范围报价的零EV门槛近似随价格反比缩放 20260425180847000
- OSK vs senolytic 的最小可比实验规格 20260425180717000
- 部分重编程 go/no-go 判据与安全边界 20260425180607000
- 皮肤顺序联合的最小分组骨架 20260425180046000
- senolytic→OSK 顺序联合的最小实验设计缺口 20260425175624000
- 零EV边界应以来源混合区间而非单点成交率表达 20260425175436000
- 零EV 边界的来源混合重算公式 20260425175246000
- senolytic→OSK 顺序联合证据缺口的三态判定语句 20260425175244000
- 来源分布对零EV边界高度敏感 20260425175033000
- 顺序联合比较必须先锁组织与读出 20260425174929000
- 自噬轴候选应分为“独立干预、上游状态与 readout”三层 20260425174343000
- 固定范围服务报价必须先过正EV门槛 20260425173625000
- 获客渠道的线索温度阶梯 20260425172527000
- 检索要用字段收缩来验证结构性空集 20260425172341000
- 研究型服务的边界语言 20260425171934000
- 骨相关系统中 senolytic→OSK 顺序实验的空检索判定 20260425171703000
- 空检索也是证据结论 20260425171236000
- 疾病背景必须与组织和终点一起匹配 20260425170821000
- 交付证据、签收动作与交接清单的最小集合 20260425170617000
- 研究型服务的明确排除项 20260425170438000
- 重编程中的 senescence 可能是阶段依赖而非单向有害 20260425170201000
- 单一组织内 senescence 负担态与生态位态的可证伪判别框架 20260425165902000
- 跨组织 head-to-head 证据缺口的并行空检索 20260425165254000
- 近邻骨关节系统也缺少 OSK vs senolytic 头对头证据 20260425165052000
- 骨组织中 OSK 与 senolytic 的最小代理终点 20260425164755000
- warm lead 原始记录的最小可核验样本模板 20260425163845000
- 首批 warm lead 回复率不能单独证明正EV 20260425163044000
- 升级路径与加购条件应以现金期望值和高信号为门槛 20260425161839000
- 试单优惠必须以首单现金期望值为约束 20260425161506000
- 单一原始正例不足以升级为普适候选 20260425161427000
- 最小交付边界必须同时锁定交付物时长与排除项 20260425161344000
- 最短回款闭环的唯一执行链 20260425160815000
- 首轮小样本实验的成功与切换判据要看红线、聚集信号和下一步 20260425154734000
- 固定范围服务的交付验收与回款闭环 20260425154639000
- 外联触达批次应由响应容量反推 20260425154608000
- 20 个潜客的周内触达应前置高温并保留响应缓冲 20260425154518000
- 先判红线，再看样本，最后看下一步 20260425154415000
- 首轮实验失败/切换触发条件要按红线、样本、下一步三层判定 20260425154400000
- Heat-shock/chaperone augmentation is not yet baseline-positive as a mammalian longevity node 20260425154317000
- 首轮实验结果分流矩阵：先硬停，再微调，后继续，最后切换 20260425154307000
- 首轮实验的切换/终止阈值要与成功阈值联动 20260425154212000
- Proteasome augmentation is not yet baseline-positive as a longevity node 20260425154052000
- 首轮小样本试验应以聚集信号与推进速度判定成败 20260425154033000
- 小样本首轮试验不要把单个高信号当成功 20260425153914000
- 不要把整类机制一刀切地排除 20260425153833000
- Mitochondrial interventions have direct lifespan-endpoint positives, but evidence is heterogeneous 20260425153808000
- 拖款、争议、变更必须三通道分治 20260425153709000
- 拖款、争议与超范围变更的最小处置规则 20260425153630000
- 默认验收要有三件套 20260425153546000
- 里程碑应对齐成本前置点 20260425153330000
- 交付证据与签收动作要把默认验收变成可执行清单 20260425153228000
- Rapamycin is a baseline-positive specific node; autophagy and mitochondria are not automatically longevity candidates 20260425153226000
- 回款先于大成本 20260425153149000
- 里程碑、预付款与尾款应按回款先于大成本来设计 20260425153106000
- 候选筛选要用“干预 + 终点”双约束检索 20260425152851000
- mTOR/rapamycin 优先于泛化自噬/线粒体作为长寿候选 20260425152830000
- 验收默认通过，争议与变更分离 20260425152826000
- 验收应默认通过，争议与变更分离 20260425152806000
- 先算响应容量，再定批次大小 20260425152609000
- 批次大小应由当日响应容量反推 20260425152550000
- 跟进记录、状态机与复盘指标要一体化设计 20260425152400000
- 跟进流程要同时闭合节奏目标与判定三层 20260425152320000
- 跟进复盘要看高信号回复率与推进速度 20260425152236000
- 跟进状态机要把无回复也当作状态 20260425152215000
- 最小跟踪字段必须覆盖五类决策 20260425152142000
- 首触达设计的三层整合：渠道、话术、判定 20260425152002000
- 转化条件、停止条件与切换规则的最小判定顺序 20260425151831000
- 跟进轮次要按唯一目标分工 20260425151755000
- 5次以内跟进的唯一目标分工 20260425151736000
- IL-11 修复代价的直接成人哺乳动物原始反例仍未检出 20260425151726000
- 跟进节奏要按来源温度分层并设停止线 20260425151710000
- 5次以内跟进的默认节奏与停止规则 20260425151655000
- 首触达A/B试验的有效性判定规则 20260425151451000
- Adult-mammal IL-11 inhibition: direct bone-homeostasis harm, fracture/wound evidence still missing 20260425151443000
- 评估首触达要看质量与推进速度 20260425151339000
- 首触达话术与渠道应看回复质量和推进效率 20260425151323000
- 记录只保留能驱动下一步决策的字段 20260425151242000
- 首触达后的最小跟踪字段与记录规范 20260425151220000
- 首触达必须先定责任人和SLA 20260425151117000
- 首触达响应时限、责任人与升级规则 20260425151039000
- 首触达回复状态的即时动作表 20260425150836000
- 首触达后先压缩成最小状态机 20260425150707000
- IL-11 longevity benefit must be decomposed into immune/inflammatory and tissue-tradeoff components 20260425150607000
- 按来源分组确定首触达渠道优先级 20260425150504000
- 首触达只做最小可回复请求 20260425150427000
- 首触达话术应短、具体、低压力且只问一个问题 20260425150406000
- IL-11 currently ranks above other screened immune/inflammation axes because it has direct mammalian healthspan/lifespan evidence 20260425150330000
- 补体级联仍未跨过通用长寿瓶颈门槛 20260425150146000
- 前 20 个潜客应按响应概率与到对话时间优先抽样 20260425150140000
- 最小可交付范围要同时写清交付物与排除项 20260425145956000
- 最小可交付范围必须同时写清交付物与排除项 20260425145936000
- IL-1/MyD88 outranks TNF/IL-6 as an upstream screening candidate, but not as a universal bottleneck 20260425145846000
- Complement cascade remains a high-potential but not yet universal longevity bottleneck 20260425145530000
- 复盘与资本再投资的一页式判定顺序 20260425145459000
- 复盘规则必须把“switch”做成可判定条件 20260425145419000
- TNF/IL-6 are low-priority control axes in longevity bottleneck screening 20260425145355000
- cGAS-STING is a strong but context-dependent aging node, not yet a universal longevity bottleneck 20260425145335000
- 复盘模板先验收决策能力 20260425145315000
- 复盘模板的最小验收标准 20260425145249000
- 周/月复盘共用一张骨架 20260425145229000
- type I interferon / JAK-STAT is an upstream amplifier, not a default universal longevity bottleneck 20260425145224000
- 周/月复盘共用模板与输出格式 20260425145213000
- 每月复盘的固定节奏 20260425145117000
- 按决策半径分层设计复盘 20260425145055000
- 每周与每月复盘的固定节奏 20260425145036000
- 先保命，再加码，最后才切换 20260425144947000
- 复盘后的决策分流应按优先级而非平均权重处理 20260425144931000
- 先设安全垫，再决定加码节奏 20260425144852000
- 现金流与资本再投资阈值 20260425144836000
- 复盘只盯能驱动资本分配的少数指标 20260425144806000
- Thymic source restoration is a strong immune upstream entry, but not yet a universal longevity bottleneck 20260425144604000
- 资源盘点要经得起分流检验 20260425144426000
- 资源盘点的审稿人检验 20260425144327000
- 资源盘点先看是否足以驱动实验 20260425144248000
- 资源盘点的完成判据 20260425144226000
- TNF/IL-6 are context-specific inflammaging mediators, not universal longevity bottlenecks 20260425144110000
- 资源盘点的最小可执行输入表 20260425144057000
- 资源/约束到首轮实验的映射规则 20260425143949000
- 硬约束先于路径排序 20260425143901000
- 硬约束优先于路径偏好 20260425143838000
- cGAS-STING is an upstream inflammaging amplifier, but not yet a universal longevity bottleneck 20260425143829000
- 先盘点资源与约束，再判断赚钱路径 20260425143735000
- 盘点可用资源的最小信息集 20260425143636000
- NLRP3 is a strong aging node but still not clearly a universal longevity bottleneck 20260425143408000
- 四类收入引擎的行动排序 20260425143248000
- 资源撮合更适合做放大器 20260425143210000
- 资源撮合的杠杆属性：放大器优先，起手式谨慎 20260425143144000
- complement 轴是高潜力候选但尚非 universal longevity bottleneck 20260425143032000
- 交易要先覆盖波动与摩擦 20260425143008000
- 投资交易的可持续性取决于边际优势是否覆盖波动与摩擦 20260425142949000
- 创业业务的风险调整期望值通常低于现金流引擎 20260425142837000
- IL-11 longevity candidacy must be split by tissue-specific tradeoffs 20260425142558000
- 用随机权重检验排序稳健性 20260425142558000
- 用随机权重检查赚钱路径排序的稳健性 20260425142539000
- 四类收入引擎的统一比较标准 20260425142428000
- 按风险调整期望值排赚钱路径 20260425142317000
- 赚钱路径的通用排序：先现金流、后可复制业务、再资产/期权 20260425142251000
- IL-1 is a strong upstream hematopoietic inflammaging loop, but not yet a universal longevity bottleneck 20260425142133000
- 先找原始因果，不用综述代替证据 20260425135741000
- IL-11 inhibition: bone-homeostasis evidence is direct, fracture-healing evidence remains missing 20260425135719000
- Adult-mammal IL-11 inhibition has clear bone-homeostasis consequences, but direct fracture/wound inhibition evidence is sparse 20260425135357000
- IL-11 still needs a pleiotropy tradeoff audit before universal-bottleneck promotion 20260425134905000
- IL-6 trans-signaling is a plausible inflammaging axis, but not a universal longevity bottleneck 20260425134712000
- IgG/FcRn is a strong immune age-amplifying axis, but not yet a universal longevity bottleneck 20260425134301000
- IL-1 outranks TNF and type I IFN as an upstream immune loop, but still falls short of a universal longevity bottleneck 20260425133745000
- 反证优先于升级候选 20260425133423000
- IL-17 / Th17 is a context-dependent inflammaging axis, not a universal longevity bottleneck 20260425133233000
- IL-11 remains the current top immune/inflammation longevity candidate, but not yet a universal bottleneck 20260425132624000
- C1q brain aging mechanism is informative but still insufficient for universal longevity candidacy 20260425131714000
- 寿命终点优先于通路热度 20260425131208000
- IL-11 is currently the strongest immune/inflammation longevity candidate in the screening set 20260425131144000
- IgG is a strong age-amplifying node, but not yet a universal longevity bottleneck 20260425130909000
- Antibody / IgG accumulation is a strong age-amplifying node, but not yet a universal longevity bottleneck 20260425130643000
- trained immunity is a functional defense amplifier, not a higher-priority longevity bottleneck than thymic source restoration 20260425130412000
- IL-1 / emergency myelopoiesis is upstream of aged HSC bias, but not yet a universal longevity bottleneck 20260425125943000
- type I interferon / JAK-STAT chronic activation is strong but context-dependent, not yet a universal bottleneck 20260425125646000
- C1q is aging-associated but not yet a universal longevity bottleneck 20260425125313000
- IL-11 is a strong lifespan-positive inflammaging node, but still not yet a universal immune bottleneck 20260425124410000
- FGF21 不是通用免疫长寿瓶颈，而是局部胸腺 niche 入口 20260425123837000
- NLRP3 is context-dependent longevity-positive, not yet a universal bottleneck 20260425051109000
- 单组织寿命正例不足以把炎症轴抬升为通用长寿瓶颈 20260425050954000
- 按因果广度而不是表面上游性来排长寿瓶颈 20260425050740000
- HSC/髓系偏置尚不能压过胸腺源恢复的免疫长寿排序 20260425050727000
- 局部语境决定抗衰老信号是否成立 20260425050544000
- Source-restoration immune entries outrank peripheral T-cell quality control when only the former has healthspan extension 20260425050521000
- Mature T-cell quality control usually ranks below thymic source restoration as a longevity entry 20260425050406000
- 免疫长寿入口的上游性排序 20260425050322000
- 免疫长寿入口的上游性排序：补给源 > 外周质量控制 > 局部 niche 维护 20260425050257000
- Peripheral T-cell quality control can reach frailty, but not yet lifespan 20260425050159000
- Peripheral T-cell quality control can reach frailty, while thymic regeneration remains mainly immune-readout level 20260425044850000
- T-cell Bcl-xL is a concrete peripheral quality-control example, but still not a validated universal longevity bottleneck 20260425044154000
- Peripheral lymph node niche repair is a lower-rank immune rejuvenation entry than thymic regeneration 20260425043703000
- Peripheral lymph node niche is a reversible immune entry, but not yet higher-leverage than thymic involution 20260425043458000
- Thymic involution remains the strongest reversible immune entry, but not yet a validated longevity bottleneck 20260425042531000
- IL-1 emergency myelopoiesis is upstream but not yet validated as a longevity bottleneck 20260425042245000
- Trained immunity is not yet a validated longevity bottleneck 20260425042105000
- 把 inflammaging 当作回路读出而非单一瓶颈 20260425041935000
- Inflammaging is better treated as a heterogeneous readout than a universal upstream bottleneck 20260425041919000
- Thymus regeneration improves immune readouts but not yet lifespan evidence 20260425041751000
- Immune rejuvenation can improve systemic aging phenotypes via thymic or peripheral routes 20260425041629000
- Immune interventions can improve systemic aging phenotypes, but not always via thymic regeneration 20260425041447000
- Immune longevity candidate ranking: thymic involution first, readouts later 20260425041227000
- 优先寻找“可逆上游入口”而不是只看年龄读出 20260425041000000
- Thymic involution can be experimentally reversed to restore naive T-cell output in aged mice 20260425040945000
- Inflammaging 更应默认按 context-dependent readout 处理 20260425040831000
- Netrin-1 可作为老化骨髓 niche 的可逆上游杠杆 20260425040329000
- Blood-aging candidate ranking: HSC exhaustion over CHIP; cell competition as framework 20260425040156000
- 先把 cell competition 当作框架，而不是立刻当作靶点 20260425040109000
- cell competition is a generic tissue-level quality-control framework 20260425040057000
- 老化干预要先找反馈回路 20260425035910000
- Bone marrow niche rejuvenation can restore aged HSC fitness 20260425035840000
- 年龄相关克隆现象优先视为读出而非总瓶颈 20260425035640000
- CHIP 更适合作为 HSC aging 的读出而非单一上游瓶颈 20260425035624000
- CDKN2A-OSK 在皮肤创面中的 FOSL1/迁移信号更应默认按间接效应解释 20260425035159000
- CDKN2A-OSK 在人皮肤创面中的直接效应与微环境间接效应应分层判断 20260425034935000
- FOSL1 不能被当成 CDKN2A-OSK 直接驱动角质形成细胞迁移的证据 20260425034652000
- 重编程效应要拆成炎症编辑与增殖激活两条轴 20260425034206000
- partial reprogramming 在人皮肤修复中更像炎症/应激状态编辑，而非增殖开关 20260425034137000
- partial reprogramming 在皮肤修复中更像炎症/应激状态编辑 20260425033952000
- 把干预时窗对齐到修复亚阶段 20260425033646000
- human skin wound-healing roadmap cleanly separates acute-support and chronic-failure programs 20260425033600000
- 修复失败常是跨细胞协同失配 20260425033050000
- chronic wound failure programs clarify which senescence states are pathological 20260425033027000
- 先锁定同组织的阶段-细胞分辨图谱 20260425032914000
- acute skin wound healing contains distinct senescent subpopulations with opposite effects 20260425032856000
- acute cutaneous wound healing is a clear example of context-dependent senescence 20260425032612000
- senolysis 可能破坏有益的再生 niche 20260425032437000
- partial reprogramming can improve regeneration by remodeling the extrinsic niche 20260425032418000
- senolysis before OSK may remove a pro-reprogramming niche in some contexts 20260425032136000
- 组合干预必须同时对齐顺序、组织和读出 20260425031020000
- 顺序联合比单药 head-to-head 更有信息量 20260425030652000
- 反证式审稿的收敛规则：比较表只能在证据边界内下结论 20260425025750000
- 路由匹配的对照实验比“同剂量”更关键 20260425023023000
- 比较干预时必须匹配给药路线 20260425022914000
- 无 head-to-head 就不要做路线优劣结论 20260425022753000
- 直接 head-to-head 证据与并列正例的判定边界 20260425022300000
- 先做同组织头对头，再谈路线优劣 20260425021502000
- 局部正例不能直接外推为长寿主路线代表性 20260425021446000
- 同一读出面板下比较长寿瓶颈候选的工程准则 20260425021221000
- 第二个长寿瓶颈候选的筛选原则 20260425021002000
- 重编程验证必须用三重读出 20260425020521000
- 功能性与组织完整性读出：部分重编程验证的最小并列面板 20260425020502000
- 表观遗传主读出设计原则：组织特异DNAm时钟优先 20260425020313000
- Partial reprogramming 的优先干预模态选择原则 20260425020147000
- 单一衰老读出不够，必须配安全反证读出 20260425015958000
- 先锁定单一可验证瓶颈，再谈宏大目标 20260425015659000
- Epigenetic information loss as a testable longevity bottleneck 20260425015600000
- 旧前缀+下一前缀联合生存刻画中性（small-case） 20260425014335000
- 旧前缀可替代嵌入不足以判别中性 20260425013950000
- 单一局部特征通常只能给出必要条件 20260425013436000
- 候选影响区不等于敏感区 20260425012422000
- 锚点固定后先局部化，再做单侧交换 20260425011113000